MedTrace Logo

Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJ-15314 Phosphate in Healthy Male Subjects

NCT04297865 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2020-03-06

No results posted yet for this study

Summary

This study aims to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of CJ-15314 phosphate in healthy male subjects.

Conditions

  • Healthy

Interventions

DRUG

A dose as CJ-15314

A dose as CJ-15314, 1 capsule

DRUG

B dose as CJ-15314

B dose as CJ-15314, 1 capsule

DRUG

C dose as CJ-15314

C dose as CJ-15314, 1 capsule

DRUG

D dose as CJ-15314

D dose as CJ-15314, 2 capsules

DRUG

E dose as CJ-15314

E dose as CJ-15314, 1 capsule

DRUG

F dose as CJ-15314

F dose as CJ-15314, 2 capsules

DRUG

Placebo

Placebo, 1 capsule

DRUG

Placebo

Placebo, 1 capsule

DRUG

Placebo

Placebo, 1 capsule

DRUG

Placebo

Placebo, 2 capsules

DRUG

Placebo

Placebo, 1 capsule

DRUG

Placebo

Placebo, 2 capsules

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Principal Investigators

  • In-Jin Jang, MD, PhD · Study Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-24
Primary Completion
2021-01-31
Completion
2021-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04297865 on ClinicalTrials.gov